Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCX-1020
- Development stage
- Discontinued
- Lead developer
- NicOx
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NCX-1020 is a nitric oxide (NO)-releasing derivative of the second-generation H1-receptor antagonist fexofenadine, developed by NicOx. The compound was designed using NicOx's proprietary nitric oxide-donating technology to combine the antihistaminic properties of fexofenadine with the anti-inflammatory and bronchodilatory benefits of nitric oxide. By releasing NO, NCX-1020 aimed to provide enhanced therapeutic effects in respiratory conditions such as allergic rhinitis and asthma, potentially reducing airway hyperresponsiveness and inflammation more effectively than fexofenadine alone. Although it underwent early-stage clinical evaluation, including Phase 1 and Phase 2 trials, development was eventually discontinued as the developer shifted its strategic focus toward ophthalmic indications.
- Other names
- Nitric oxide-releasing fexofenadineNO-fexofenadine
02
Targets
sGC (Soluble Guanylyl Cyclase)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on NCX-1020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCX-1020.